Biomarkers /
PML
Overview
Promyelocytic leukemia (PML) is a gene that encodes a protein that functions as a transcription factor and tumor repressor in nuclear bodies. The protein also regulates the p53 response to oncogenic signals. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as bone cancer, intestinal cancer, and stomach cancer.
Biomarker-Directed Therapies
Clinical Trials
Significance of PML in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.